AU4101396A - Synthesis of 35s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide - Google Patents
Synthesis of 35s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxideInfo
- Publication number
- AU4101396A AU4101396A AU41013/96A AU4101396A AU4101396A AU 4101396 A AU4101396 A AU 4101396A AU 41013/96 A AU41013/96 A AU 41013/96A AU 4101396 A AU4101396 A AU 4101396A AU 4101396 A AU4101396 A AU 4101396A
- Authority
- AU
- Australia
- Prior art keywords
- benzodithiol
- acid
- dioxide
- synthesis
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims description 43
- 230000015572 biosynthetic process Effects 0.000 title description 27
- 238000003786 synthesis reaction Methods 0.000 title description 26
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title description 23
- 238000000034 method Methods 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 17
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 13
- 230000002194 synthesizing effect Effects 0.000 claims description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 9
- 238000002372 labelling Methods 0.000 claims description 9
- 230000001590 oxidative effect Effects 0.000 claims description 9
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000005987 sulfurization reaction Methods 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- -1 oxone Chemical compound 0.000 claims description 6
- 229940103494 thiosalicylic acid Drugs 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 239000007800 oxidant agent Substances 0.000 claims description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 4
- XYPISWUKQGWYGX-UHFFFAOYSA-N 2,2,2-trifluoroethaneperoxoic acid Chemical compound OOC(=O)C(F)(F)F XYPISWUKQGWYGX-UHFFFAOYSA-N 0.000 claims description 2
- 229910019093 NaOCl Inorganic materials 0.000 claims description 2
- 229910019891 RuCl3 Inorganic materials 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 claims description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims 2
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 claims 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 10
- 150000008300 phosphoramidites Chemical class 0.000 description 9
- DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical compound CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000074 antisense oligonucleotide Substances 0.000 description 5
- 238000012230 antisense oligonucleotides Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- UIJGNTRUPZPVNG-UHFFFAOYSA-N benzenecarbothioic s-acid Chemical compound SC(=O)C1=CC=CC=C1 UIJGNTRUPZPVNG-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 4
- JUDOLRSMWHVKGX-UHFFFAOYSA-N 1,1-dioxo-1$l^{6},2-benzodithiol-3-one Chemical compound C1=CC=C2C(=O)SS(=O)(=O)C2=C1 JUDOLRSMWHVKGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101100046831 Drosophila melanogaster Tpst gene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 150000008298 phosphoramidates Chemical class 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- GDSOQCSYONDNAJ-UHFFFAOYSA-N 2-thiophen-2-ylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=CS1 GDSOQCSYONDNAJ-UHFFFAOYSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- 229920006063 Lamide® Polymers 0.000 description 1
- WXJXBKBJAKPJRN-UHFFFAOYSA-N Methanephosphonothioic acid Chemical class CP(O)(O)=S WXJXBKBJAKPJRN-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- ZMJRWBOSGFHETL-UHFFFAOYSA-N [O-]C(C[S+]1C=CC=C1)=O Chemical compound [O-]C(C[S+]1C=CC=C1)=O ZMJRWBOSGFHETL-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
SYNTHESIS OF 35S-LABELED OLIGONUCLEOTIDES WITH 3H-1 ,2-BENZ0DITHI0L-3~1 , 1-
BACKGROUND OF THE INVENTION Field of the Invention
The invention relates to synthesis of 35S-labeled 3H-1,2 benzodithiol-3-one-l,l dioxide (1) and its use in the preparation of site-specifically 35S-labeled oligonucleotides.
Description of the Prior Art
Since Zamecnik and Stephenson, Proc. Natl. Acad. Sci. USA 75, 280-284 (1978) first demonstrated virus replication inhibition by synthetic oligonucleotides, great interest has been generated in oligonucleotides as therapeutic agents. In recent years, the development of oligonucleotides as therapeutic agents and as agents of gene expression modulation has gained great momentum. The greatest development has been in the use of so-called antisense oligonucleotides, which form Watson-Crick duplexes with target rnRNAs. Agrawal, Trends in Biotechnology 10, 152-158 (1992), extensively reviews the development of antisense oligonucleotides as antiviral agents. See also Uhlmann and Peymann, Chem. Rev. 90, 543 (1990).
Various methods have been developed for the synthesis of oligonucleotides for such purposes. See generally, Methods in Molecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs (S. Agrawal, Ed., Humana Press, 1993); Oligonucleotides and Analogues: A Practical Approach (F. Eckstein, Ed., 1991); Uhlmann and Peyman,
supra. Early synthetic approaches included phosphodiester and phosphotriester chemistries. Khorana et al., J. Molec. Biol. 72, 209 (1972) discloses phosphodiester
chemistry for oligonucleotide synthesis. Reese, Tetrahedron 34, 3143-3179 (1978), discloses phosphotriester chemistry for synthesis of oligonucleotides and polynucleotides.
These early approaches have largely given way to the more efficient phosphoramidite and
H-phosphonate approaches to synthesis. Beaucage and Caruthers, Tetrahedron Lett. 22, 1859- 1862 (1981 (reviewed in Beaucage and Iyer, Tetrahedron 48, 2223 ( 1992)), discloses the use of deoxynucleoside phosphoramidites in polynucleotide synthesis. Agrawal and
Zamecnik, U.S. Patent No. 5,149,798 (1992), discloses optimized synthesis of oligonucleotides by the H-phosphonate approach.
Both of these modern approaches have been used to synthesize oligonucleotides having a variety of modified internucleotide linkages. Agrawal and Goodchild,
Tetrahedron Lett. 28, 3539-3542 (1987), report synthesis of oligonucleotide methylphosphonates using phosphoramidite chemistry. Connolly et al., Biochemistry 23, 3443 (1984), discloses synthesis of oligonucleotide phosphorothioates using phosphoramidite chemistry. Jager et al., Biochemistry 27, 7237 (1988), discloses synthesis of oligonucleotide phosphoramidates using phosphoramidite chemistry. Agrawal et al.,
Proc. Natl. Acad. Sci. USA 85, 7079-7083 (1988), discloses synthesis of oligonucleotide phosphoramidates and phosphorothioates using H-phosphonate chemistry.
The use of 3H- 1 ,2 benzodithiol-3-one- 1 , 1 dioxide (1) as a sulfurizing reagent, (Iyer et al., J. Am. Chem. Soc. 112, 1253-1254 (1990)) in conjunction with phosphoramidite chemistry (Beaucage and Caruthers, Tetrahedron Lett. 22, 1859- 1862 (1981) and Beaucage and Iyer, Tetrahedron 48, 2223-231 1 (1992)) is now well established for the routine synthesis and large-scale manufacture of a variety of oligonucleoside phosphorothioates. Use of this reagent for the synthesis of methylphosphonothioates and other analogs has
been reported. Padmapriya et al., Antisense Res. ά Dev. 4, 185-199 ( 1994) and Andrad et al., Bioorg. & Med. Chem. Lett. pp. 2017-2022 (1994). For biological studies, 35S- labeled oligonucleoside phosphorothioates are prepared using the alternate chemistry viz.,
H-phosphonate chemistry. Garegg et al., Chem. Scr. 25, 280-282 (1985). It is difficult to achieve site-specific labeling of phosphorothioates using H-phosphonate chemistry, however, and it is inconvenient to carry out preparation of 35S-labeled oligonucleoside phosphorothioate constructs, such as those with (a) mixed ribonucleotide- deoxyribonucleotide population ("hybrid oligos"), (b) heterogeneous backbones, e.g., deoxyribonucleotide-methyl phosphonate ("chimeric oligos") and (c) mixed phosphodiester-phosphorothioate (PO-PS) backbones. In order to ensure stereochemically
"uniform" product, it is desirable to follow the same chemistry both for synthesis and biological evaluation. The disadvantages of using elemental sulfur have also been recognized. Iyer et al., J. Am. Chem. Soc. 112, 1253-1254 (1990) and Iyer et al., J. Org. Chem. 55, 4693-4698 (1990). In vivo pharmacokinetic studies of pharmalogical compounds, e.g., antisense oligonucleotide phosphorothioates (Agrawal et al., Proc. Natl. Acad. Sci. U.S.A. 88, 7595- 7599 (1991)) requires labelling the compounds to enable detection. 35S-labelling is an established and wide-spread technique. In view of the aforementioned difficulties in synthesizing 35S-labeled oligonucleoside phosphorothioate constructs, improved methods are desirable.
SUMMARY OF THE INVENTION The present invention provides new compounds and improved methods for synthesizing 35S-labeled oligonucleoside phosphorothioates. This invention comprises
several aspects. In the first aspect, the present invention provides a novel compound useful for synthesizing oligonucleotide phosphorodiioates labelled with 33S. This compound, 35S-3H-l,2-benzodithiol-3-one-l,l dioxide (1), has the structure
wherein the asterisk denotes the 35S label.
In a second aspect of the invention, a new method of synthesizing 35S-3H-1,2- benzodithiol-3-one-l,l dioxide (1) is provided. An important consequence of this method is that it allows for the preparation of a variety of 35S-labeled oligonucleotide phosphorothioates and thereby facilitates pharmacokinetic studies of these compounds. The method of synthesizing 3$S-3H-l,2-benzodithiol-3-one-l,l dioxide (1) is depicted in Fig. 2 and comprises first contacting 35S-thiobenzoic acid (4) with thiosalicylic acid (5) to yield the condensation product, 35S-3 H 1 ,2-benzodithiol-3-one (2). 35S-3 H 1 ,2- benzodithiol-3-one (2) is then oxidized to yield the desired product, 35S-3H-1,2- benzodithiol-3-one-l,l dioxide (1).
In the third aspect of the invention, a new method of synthesizing 35S-labelled oligonucleotides is provided. This method comprises contacting 35S-3H-l,2-benzodithiol- 3-one-l,l dioxide (1) with an oligonucleotide susceptable to oxidative sulfurization. The method of 35S labelling an oligonucleotide synthesized via the phosphoramidite method is depicted in Fig. 3. Other methods are contemplated, however, such as oxidative
sulfurization of alkyl- and/or aryl-phosphites to yield the corresponding 35S-labelled alkyl- and/or aryl-phosphonothioate.
Those skilled in the art will appreciate that 35S-3H-l,2-benzodithiol-3-one-l,l dioxide (1) can be used for any purpose and in any way that its unlabelled analog, 3H-1,2- benzodithiol-3-one-l,l dioxide, can be used.
The foregoing merely summarizes certain aspects of the present invention and is not intended, nor should it be construed, to limit the invention in any way.
All patents and other references cited in this specification are hereby incorporated by reference in their entirety.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 depicts the synthesis of 35S-thiobenzoic acid (4) from 35S elemental sulfur and thiobenzoic acid.
Figure 2 depicts the synthesis of 35S-3H-l,2-benzodithiol-3-one-l,l dioxide (1) from 35S-thiobenzoic acid (4) and thiosalicylic acid (5) via the intermediate 35S-3H-1,2- benzodithiol-3-one (2).
Figure 3 depicts the 3S labelling of an oligonucleotide synthesized by the phosphoramidate method.
Figure 4 is a RP-ΗPLC profile of 35S-Λp-d[TpsT] and 35S-Sp-d[TpsT] by UV detection at λ=260 nm (Panel A) and by flow scintillation Analysis (Panel B).
Figure 5 displays 35S-labelled oligonucleotides synthesized according to the methods of the present invention.
Figure 6 displays and autoradiogram of oligonucleotides SEQ. ID NOs. 5-7
(purified) and SEQ. ID. NO. 8 (crude) subjected to PAGE.
Figure 7 displays an ion-exchange HPLC profile of 35S-labelled SEQ. ID. NO. 5 as detected by UV absorbance at λ=260 nm (Panel A) and by flow scintillation analysis
(Panel B).
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Because of the ever-increasing interest in antisense oligonucleotides as therapeutic agents, there is a need to provide methods whereby the pharmacokinetic properties of these compounds can be tested. It is necessary to determine biodistribution, as well as to determine the half-lives and degradation products. One method of accomplishing these tasks is to label the oligonucleotides with 35S, a common isotopic label used for tracing and detecting biological compounds.
The present invention provides a new compound useful for synthesizing 35S- labelled antisense oligonucleotides, a new method of synthesizing the compound and new methods for 3SS-labelling oligonucleotides.
The first aspect of the invention comprises a new compound, 35S-3H-1,2- benzodithiol-3-one-l,l dioxide (1), having the following structure
wherein the asterisk indicates the position of the 35S radionucleotide.
The non-radiolabelled analog, 3H-l,2-benzodithiol-3-one-l,l dioxide, is known (e.g., Beaucage, Regan and Iyer U.S. Patent No. 5,003,097 (Beaucage et al. '097) and Iyer et al., J. Am. Chem. Soc. and J. Org. Chem., supra), but the 3SS-labelled compound has never before been synthesized.
Those skilled in the art will appreciate that 35S-3H-l,2-benzodithiol-3-one-l,l dioxide (1) can be used for the same purposes and in the same manner as its non- radiolabelled counterpart. A second aspect of the invention comprises a new method of synthesizing 35S -3H-l,2-benzodithiol-3-one- 1,1 dioxide. This method is a modification of the method of Beaucage et al. '097, for example. An important benefit of this method is that it enables production of 35S-3H-l,2-benzodithiol-3-one-l,l dioxide (1). In contradistinction to prior art methods, the method of this invention uses a reactant in which the 35S label is easily incorporated. The prior art teaches that the precursor to 3H-l,2-benzodithiol-3-one-l,l dioxide,
3H-l,2-benzodithiol-3-one, can be produced by mixing 2-thiolbenzoic acid and thiolacetic acid in sulfuric acid. E.g., Beaucage et al. '097. To have the 35S in the appropriate position in the final product using this method, it is necessary to incorporate the 35S in the
thiolacetic acid. We attempted the preparation of 35S-thiolacetic acid by a high temperature (125°C) exchange reaction between thiolacetic acid and elemental 35S using a reported procedure. Kawamura et al., Chem. Lett. 1231-1234 (1975). The high volatility
(b.p. 81 °C) and vapor pressure of thiolacetic acid posed problems, however, when using 35S with high specific activity (32 mCi/μmol), and the 35S-labelled thiolacetic acid could not be isolated with high specific activity.
To circumvent the difficulty encountered by trying to 35S label thiolacetic acid, we sought a thiol acid with a higher boiling point and lower vapor pressure. The commercially available thiobenzoic acid (4) seemed an ideal candidate. Before using 3ϊS-4 in the preparation of 1, we validated the use of 4 in the synthesis of 1, by preparing 3$S-
3H-l,2-benzodithiol-3-one (2), the precursor to 1 (Fig. 2). Although we do not wish to be bound by any theory, and, indeed, this synthetic method does not depend on any theory, presumably 2 is formed (McKibben and McClelland, J. Chem. Soc. 170-173
(1923)) via the intermediate 3:
A longer time (4 hours) was required for completion of the reaction, although the yield
(ca. 60%) was somewhat lower than when thiolacetic acid is use (ca. 80%). A crystallized sample of 2, thus synthesized, was identical in all respects (m.p., Η-NMR and l3C-NMR) to that obtained by the reported procedure using thiolacetic acid Iyer et al., J. Am. Chem.
Soc. 112, 1253-1254 (1990) and Iyer et al. J. Org. Chem. 55, 4693-4698 (1990). Having demonstrated the feasibility of using 4 in the preparation of 2, 35S-4 was conveniently prepared (Fig. 1) in high radiochemical yield (78%). 35S-4 thus obtained was converted to 35S-2 (Fig. 2), which, when subjected to carefully controlled oxidation, using hydrogen peroxide in trifluoroacetic acid. Iyer et al., J. Am. Chem. Soc. 112, 1253-1254 (1990) and
Iyer et al. J. Org. Chem. 55, 4693-4698 (1990). It is important to avoid use of excess
H2O2. The desired product 35S-1 as a white crystalline solid in 30% chemical yield (based on the amount of 5 used) and having a specific activity of 90 μCi/μmol. The reaction mixture should be worked up immediately after its completion to avoid decomposition of 35S-1.
Thus, the synthetic method according to this aspect of the invention comprises first contacting 35S-thiobenzoic acid (4) with thiosalicylic acid (5) to yield the condensation product, 35S-3 H l,2-benzodithiol-3-one (2). This reaction is acid catalyzed. In a preferred embodiment sulfuric acid is used, although any suitably strong acid may be used. 35S-3H 1 ,2-benzodithiol-3-one (2) is then oxidized to yield the desired product, 5S-3H- 1 ,2- benzodithiol-3-one-l,l dioxide (1). Any suitably strong oxidizing agent may be used, e.g., hydrogen peroxide and trifluoroacetic acid, trifluoro peroxyacetic acid or other oxidizing agents such as oxone, sodium periodate NaOCl, RuCl3 and reagents used in the oxidation of sulfide to sulfone. See, e.g., M. Ηudlicky, Oxidation in Organic Chemistry, ACS Monograph 186, 1990. In a preferred embodiment, oxidation is accomplished with hydrogen peroxide and trifluoroacetic acid. This scheme is depicted in Fig. 2.
The third aspect of the present invention comprises a new method for 35S-labelling oligonucleotides. The method can be used to selectively place the 3$S at any desired
internucleoside linkage. Anywhere from one to all internucleoside linkages may be labelled with 35S. The method comprises contacting 35S-3H-l,2-benzodithiol-3-one-l,l dioxide (1) with an oligonucleotide susceptible to oxidative sulfurization. In a preferred embodiment, the oligonucleotide is synthesized by the phosphoramidite method, and 35S- 3H- 1 ,2-benzodithiol-3-one- 1 , 1 dioxide (1) is contacted with the oligonucleotide having one or more β-cyanoethyl phosphotriester internucleoside linkages under standard conditions known in the art. In another preferred embodiment, an oligonucleotide having one or more alkyl- and/or aryl-phosphite internucleotide linkages is contacted with 35S-3H-1,2- benzodithiol-3-one-l,l dioxide (1) to yield the corresponding 35S-labelled alkyl- and/or aryl-phosphonothioate. This reaction, using the non-radiolabeled oxidative sulfurization agent, is taught by Padmapriya et al., supra.
Those of skill in the art will appreciate that 35S-3H-l,2-benzodithiol-3-one-l,l dioxide (1) can be used to 35S-label any compound that is capable of being sulfurized by the unlabeled analog 3H-l,2-benzodithiol-3-one-l,l dioxide. For instance, the present method is capable of 35S labelling carbohydrates, proteins, and any macromolecule into which one can incorporate an 35S label by oxidative thiolation. Thus, RNA can be labelled with 3SS in a site-specific manner, as can phosphopeptides. Phosphorothioate and sulfur analogs of phospholipids, glycerophospholipids, and phosphocar bohydtrates (e.g., myoinositol phosphates or their conjugates with other macromolecules) can also be labeled with 35S. 35S can be inserted into thiophosphates and thiotriphosphates (e.g., ATP) and then incorporated into any molecule using chemical or enzymatic phosphorylation reactions.
The following examples are provided for illustrative purposes only and are not intended, nor should they be construed, to limit the invention in any way.
EXAMPLES Example 1
Synthesis of "S-3H-1 ,2-benzodithiol-3-one-l , 1 dioxide (I) Synthesis of 35S-3H-1.2-benzodithiol-3-one (2)
A solution of 35S (5 mCi in 100 μl of toluene) (Amersham, England) and 6.5 μl (55 μmol) of unlabelled thiobenzoic acid (Aldrich, Milwaukee, WI) were placed in a 1.5 ml Eppendorf tube and the contents heated at 97°C for 5 hours. The solution was evaporated to dryness under argon and 5 mg of thiosalicylic acid (Aldrich, Milwaukee,
WI) was added. The reaction mixture was cooled to 0°C and sulfuric acid (98%, 50 ml,
(J.T. Baker, Phillipsburg, NJ) was added. The mixture was kept at 50°C for 3 hours. The resulting brown reaction mixture was cooled to -78°C and 600 μl of water was added.
The solution was extracted with methylene chloride (4 X 3 ml) (VWR, Westchester, PA) and the organic layer washed with Na,CO3 (5%, 2 X 2 ml). (EM Science, Gibbstown, NJ).
The organic layer was evaporated to dryness under a stream of argon to give a yellow solid. The material was then dissolved in 3 ml of warm hexane (J.T. Baker, Phillipsburg, NJ). and after centrifugation the supernatant solution was evaporated to dryness under argon to give a pale yellow solid (4 mg, 44% yield). This material could be used in the next step without additional purification and was stored at -20°C until ready to use.
Synthesis of 35S-3H-1.2-benzodithiol-3-one-l.l dioxide (1) from 35S-3H-1.2-benzodithiol- 3-one (2)
To a 1.5 ml Eppendorf tube containing 4 mg of 35S-3H-l,2-benzodithiol-3-one (2)
(prepared as described above), both of which had been cooled to 0°C, 25 ml of trifluroacetic acid (Aldrich, Milwaukee, WI) and 12 ml 30% hydrogen peroxide (Aldrich,
Milwaukee, WI) were added. The reaction mixture was warmed to 42°C. After about 2 hours (as monitored by TLC, silica gel, chloroform Iyer et al., J. Org. Chem.), the reaction mixture was cooled to 0°C and 300 ml of water added. A white precipitate of
3SS-3H-l,2-benzodithiol-3-one-l,l dioxide (1) was immediately formed. The slurry was centrifuged and the precipitate washed with water (2 X 300 μl) and dried in vacuo to give
2 mg of 3iS-3H-l,2-benzodithiol-3-one-l,l dioxide (1) (total activity of 350 μCi, specific activity 90 μCi/μmol).
A solution of 35S-3H-l,2-benzodithiol-3-one-l,l dioxide (1) in anhydrous acetonitrile (2 mg, 90 μCi/μmol in 200 ml acetonitrile) was used for the oxidative sulfurization reaction described below. The solution could be stored at -20°C until ready for use.
Example 2
Synthesis ofiSS-labelled Oligonucleotides
In order to demonstrate the use of 35S-3H-l,2-benzodithiol-3-one-l,l dioxide (1) in the preparation of oligonucleotides, we prepared 35S-d[TpsT] (where the "ps" stands for phosphorothioate internucleoside linkage) on a 0.1 μmol scale in an automated DNA synthesizer using phosphoramidite chemistry. Beaucage and Caruthers, Tetrahedron Lett.
22, 1859-1862 (1981) and Beaucage and Iyer, Tetrahedron 48, 2223-231 1 (1992). To incorporate the 35S label, the synthesis cycle was interrupted after the formation of the internucleotidic phosphite linkage. The CPG was removed from the column and treated with a solution of (15 ml, 90 μCi/μmol, 30 min.) followed by treatment with a solution of "cold" (i.e., non-35S labelled) 3Η-l,2-benzodithiol-3-one-l,l dioxide (2% in acetonitrile,
100 ml, 10 min). A sample of the (TpsT) prepared under the exact conditions employing
"non-radioactive" 1 revealed that the conversion of TpsT was >99%.
The oxidative-sulfurization was quantitative as determined by "trityl assays" conducted during the synthesis. Agrawal, Protocols in Molecular Biology, supra. After cleavage from the CPG and phosphate deprotection with aqueous ammonium hydroxide
(30%, 2 hours, 35°C) the dimer was examined by poly aery lamide gel electrophoresis
(PAGE, 20%). The autoradiographic image was superimposable on its UV-shadowed band. When subjected to reverse-phase HPLC employing a UV detector interfaced with a radiochemical detector, its radioactivity profile was superimposable on the UV-absorbing peaks, corresponding to retention times of Rp-35S-d[TpsT] (retention time = 22.7 min) and
Sp-35S-d[TpsT] (retention time = 24.0 min) (Fig. 4, Panel A). ("Rp" and "Sp" represent the two configurations at the chiral phosphorous center.) Detection by flow scintillation
analysis is display in Fig. 4, Panel B. HPLC analysis was done with a Waters column
(Milford, MA) equipped with a photodiode array UV detector interfaced with a
Radiomatic (Meriden Ct., MA) 500 TR v3.00 radiochemical detector using 8NV C,g 4μ
Radial Pak (Waters, Milford, MA) cartridge column, gradient (100% A to 60% B over 60 minutes) of buffer A (0.1M CH3CO2NH4) and buffer B (80:20, CH3CN:0.1 M
CH3CO2NH<), flow rate 1.5 ml min.
We then prepared on a 1 μmol scale a variety of oligonucleotides (SEQ ID NOs
1-4) bearing a pre-determined site of incorporation of the 35S-label. As displayed in Fig.
5, all internucleotide linkages are phosphorothioates, except as indicated. The arrows indicate the 3 S-label site. For site specific incorporation of the 35S label, the synthesis cycle was interrupted at the desired point and treated with 35S-3H- 1 ,2-benzodithiol-3-one- 1,1 dioxide (1) (50 μl, 90 μCi/μmol, 30 min) as before. The oxidative-sulfurization was quantitative as determined by "trityl assays" conducted during the synthesis.
After deprotection with ammonium hydroxide (30%, 10 hour, 55°C), the crude oligonucleotides (SEQ ID NOs 1-4) were purified by preparative PAGE, desalted by
Sephadex G-25 chromatography, lyophilized dry and subjected to analytical PAGE (Fig. 6). The oligonucleotides (SEQ ID NOs 1-4) thus obtained had a specific activity of about 23 ~ 25 μCi/μmol.
We subjected 35S-labelled SEQ. ID. NO. 5 to ion-exchange ΗPLC and detected the eluant by UV detection at λ=260 nm (Fig. 7, Panel A) and by flow scintillation analysis
(Fig. 7, Panel B). Ion-exchange ΗPLC was done using a GEN-PAK FAX column (4.6 X 100 mm) at 65°C using a gradient (80% A to 100 % B over 50 min.) of Buffer A (25 raM Tris ΗCL. pΗ 8.5, 10% CΗ3CN) to Buffer B (25 mM Tris HC1, 2 M LiCl, pH 8.5,
% CH3CN) and a flow rate of 0.5 ml/min.
Claims (9)
1. A 35S containing compound having the structure:
wherein the asterisk indicates the 35S.
2. A method of synthesizing the compound of claim 1 comprising contacting thiosalicylic acid with 35S-thiobenzoic acid in acid medium and oxidizing the reaction product.
3. The method of claim 2 wherein oxidation of the reaction product is accomplished with an oxidizing agent selected from the group consisting of trifluoroacetic acid and hydrogen peroxide, trifluoroperoxyacetic acid, oxone, sodium periodate, NaOCl, and RuCl3.
4. A method of synthesizing the compound of claim 1 comprising oxidizing 35S-3H- l,2-benzodithiol-3-one, which has the structure
wherein the asterisk indicates the position of the 35S.
5. The method of claim 4 wherein the oxidizing agent is a mixture of trifuoroacetic acid and hydrogen peroxide.
6. The method of claim 4 wherein the 35S-3H-l,2-benzodithiol-3-one is synthesized by contacting thiosalicylic acid with 35S-thiobenzoic acid in acid medium.
7. A method of 35S-labelling an oligonucleotide comprising contacting the compound of claim 1 with an oligonucleotide susceptible to oxidative sulfurization.
8. The method according to claim 7 wherein the oligonucleotide has from one to all β-cyanoethyl phosphoramidite internucleoside linkages.
9. The method according to claim 7 wherein the oligonucleotide has from one to all alkyl or aryl phosphite internucleoside linkages.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US335100 | 1994-11-07 | ||
US08/335,100 US5833944A (en) | 1994-11-07 | 1994-11-07 | Procedure for the solid phase synthesis of 35 S-labeled oligonucleotides with 3H-1,2-benzodithiol-3-one-1,1-dioxide |
US49325795A | 1995-06-21 | 1995-06-21 | |
US49333995A | 1995-06-21 | 1995-06-21 | |
US493339 | 1995-06-21 | ||
US493257 | 1995-06-21 | ||
PCT/US1995/014259 WO1996014277A1 (en) | 1994-11-07 | 1995-11-06 | Synthesis of 35s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide |
Publications (1)
Publication Number | Publication Date |
---|---|
AU4101396A true AU4101396A (en) | 1996-05-31 |
Family
ID=27407027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU41013/96A Abandoned AU4101396A (en) | 1994-11-07 | 1995-11-06 | Synthesis of 35s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0790965A1 (en) |
JP (1) | JPH10509447A (en) |
CN (1) | CN1165508A (en) |
AU (1) | AU4101396A (en) |
WO (1) | WO1996014277A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1667522B1 (en) | 2003-09-09 | 2018-01-17 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
JOP20200257A1 (en) | 2014-05-01 | 2017-06-16 | Geron Corp | Oligonucleotide Compositions and Methods of Making the Same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5003097A (en) * | 1989-10-02 | 1991-03-26 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the sulfurization of phosphorous groups in compounds |
-
1995
- 1995-11-06 JP JP8515428A patent/JPH10509447A/en active Pending
- 1995-11-06 CN CN 95196093 patent/CN1165508A/en active Pending
- 1995-11-06 AU AU41013/96A patent/AU4101396A/en not_active Abandoned
- 1995-11-06 WO PCT/US1995/014259 patent/WO1996014277A1/en not_active Application Discontinuation
- 1995-11-06 EP EP95939047A patent/EP0790965A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO1996014277A1 (en) | 1996-05-17 |
CN1165508A (en) | 1997-11-19 |
EP0790965A1 (en) | 1997-08-27 |
JPH10509447A (en) | 1998-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1028124B2 (en) | Improved deprotection method for the synthesis of oligomeric compounds | |
US6639088B2 (en) | Compounds for protecting hydroxyls and methods for their use | |
CA2627208C (en) | Polynucleotide containing a phosphate mimetic | |
US6531590B1 (en) | Processes for the synthesis of oligonucleotide compounds | |
Mag et al. | Synthesis and selective cleavage of an oligodeoxynucleotide containing a bridged intemucleotide 5′-phosphorothioate linkage | |
US6291669B1 (en) | Solid phase synthesis | |
US6846922B1 (en) | Activators for oligonucleotide synthesis | |
US6169177B1 (en) | Processes for the synthesis of oligomeric compounds | |
JPH05504552A (en) | Oligonucleotide modified at the 2' position | |
KR0151153B1 (en) | Oligonucleotide sequence of counter messenger RNA opposite to alpha TNF, method of preparation, use as medicament and pharmaceutical composition | |
US6310198B1 (en) | Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks | |
EP1244682A1 (en) | Process for the preparation of oligomeric compounds | |
US5833944A (en) | Procedure for the solid phase synthesis of 35 S-labeled oligonucleotides with 3H-1,2-benzodithiol-3-one-1,1-dioxide | |
WO1997029116A1 (en) | Sulphur containing dinucleotide phosphoramidites | |
AU4101396A (en) | Synthesis of 35s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide | |
NZ261480A (en) | Preparation of dimeric nucleotide derivatives containing phosphonothionate internucleotide linkages | |
Krotz et al. | Phosphorothioate oligonucleotides: largely reduced (N-1)-mer and phosphodiester content through the use of dimeric phosphoramidite synthons | |
Karamychev, Michael W. Reed, Ronald D. Neumann, Igor G. Panyutin | Distribution of DNA strand breaks produced by iodine-123 and indium-111 in synthetic oligodeoxynucleotides | |
US5847104A (en) | Method of tritium labeling oligonucleotide | |
US5631361A (en) | Method of synthesizing radioisotopically labeled oligonucleotides by direct solid-phase 5' phosphitylation | |
US5668262A (en) | Method of tritium labeling oligonucleotides | |
US5639875A (en) | Methods for H-phosphonate syntheis of oligonucleotides using triphosgene | |
Iyer et al. | Synthesis of [35S] 3H-1, 2-benzodithiole-3-one-1, 1-dioxide: Application in the Preparation of site-specifically 35S-labeled oligonucleotides | |
Sasmor et al. | A practical method for the synthesis and purification of 14C labeled oligonucleotides | |
Capobiancoa et al. | Conjugated oligonucleotides for biochemical applications |